Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | ESRRA | P11474 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5150644 | 0.82 | POLB (0.40) | ALDH1A1GAAMAPTPOLB | |
| SCHEMBL5149065 | 0.80 | ADORA2A (0.34) | CES2CES1ELANEALDH1A1MAPT | |
| SCHEMBL6133646 | 0.74 | PTPN1 (0.39) | CES2CES1ELANEALDH1A1GAA | |
| SCHEMBL6134172 | 0.74 | SLC6A2 (0.44) | ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL11769973 | 0.70 | ALDH1A1 (0.55) | CES2CES1ELANEALDH1A1ALOX15 | |
| SCHEMBL5388545 | 0.69 | LMNA (0.39) | CES2CES1ELANEALDH1A1GAA | |
| SCHEMBL6133369 | 0.69 | LMNA (0.39) | CES2CES1ALDH1A1GAAMAPT | |
| SCHEMBL6133458 | 0.68 | CYP11B1 (0.40) | CES2CES1ELANEALDH1A1GAA | |
| SCHEMBL6133456 | 0.68 | CYP11B1 (0.40) | CES2CES1ELANEALDH1A1GAA | |
| SCHEMBL11747570 | 0.67 | CES2 (0.66) | CES2CES1ALDH1A1ALOX15GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1441732-A2 | THIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003039451-A2 | THIAZOLE PYRIDAZINONES AS ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | MC2R, CYP2C9, OXTR | CES2 1877/4885CES1 1489/4885ELANE 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.